GPER activation attenuates cardiac dysfunction by upregulating the SIRT1/3-AMPK-UCP2 pathway in postmenopausal diabetic rats.
Level 5 - mechanism / opinion, no new human data
Animal experimental study (Oxford CEBM Level 5 / mechanism-based preclinical research)
PubMed 38134189 · doi:10.1371/journal.pone.0293630
What was done
Female rats were divided into five experimental groups: Sham-Control, type 2 diabetes (T2D, induced by high-fat diet/streptozotocin), ovariectomized T2D (OVX+T2D), OVX+T2D+Vehicle, and OVX+T2D+G-1 (a GPER agonist). G-1 was administered for six weeks. Left ventricular hemodynamic parameters, myocardial oxidative stress biomarkers, and protein expression of sirtuins (Sirt1/2/3/6), p-AMPK, and UCP2 were measured via Western blot.
What was found
The abstract reports directional changes without numeric values or effect sizes. T2D induced left ventricular dysfunction, oxidative stress, and decreased Sirt1/2/3/6, p-AMPK, and UCP2 levels, which were further aggravated by ovariectomy. Six weeks of G-1 treatment ameliorated the hemodynamic impairment, improved oxidative status, and upregulated protein expression of Sirt1, Sirt3, p-AMPK, and UCP2 in OVX+T2D rats.
Why it matters
These findings delineate a possible mechanistic link between GPER activation and the SIRT1/3-AMPK-UCP2 signaling axis in postmenopausal diabetic cardiac dysfunction, identifying potential targets for preclinical drug development.
Limits
This is an animal model study with no direct human validation. The abstract reports no numerical values, confidence intervals, p-values, or sample sizes (n). Functional cardiac rescue was evaluated via hemodynamic markers, but long-term survival or adverse effects of G-1 were not reported.
Cited by
- supports Loss of estrogen leads to loss of NRF2 induction, SIRT1 activation, and AMPK activation.